Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
16 February 2018 - 12:00AM
Immunomedics, Inc., (NASDAQ:IMMU)
(“Immunomedics” or the “Company”) today announced that Michael
Pehl, President and Chief Executive Officer, will participate in a
fireside chat at the RBC Capital Markets 2018 Global Healthcare
Conference on Thursday, February 22, 2018 at 3:05 p.m. Eastern Time
at the Lotte New York Palace, New York, N.Y. A live audio webcast
of the fireside chat will be accessible from the Company’s website
at https://immunomedics.com/investors/.
About ImmunomedicsImmunomedics
is a clinical-stage biopharmaceutical company developing monoclonal
antibody-based products for the targeted treatment of cancer and
other serious diseases. Immunomedics’ corporate objective is to
become a fully-integrated biopharmaceutical company and a leader in
the field of antibody-drug conjugates. To that end, Immunomedics’
immediate priority is to commercialize its most advanced product
candidate, sacituzumab govitecan (IMMU-132), beginning in the U.S.,
with metastatic triple-negative breast cancer as the first
indication. For additional information on the Company, please visit
its website at https://immunomedics.com/. The information on its
website does not, however, form a part of this press release.
Cautionary note regarding
forward-looking statementsThis release, in addition to
historical information, may contain forward-looking statements made
pursuant to the Private Securities Litigation Reform Act of 1995.
Such statements, including statements regarding clinical trials
(including the funding therefor, anticipated patient enrollment,
trial outcomes, timing or associated costs), regulatory
applications and related timelines, including the anticipated
filing timeline for the BLA, out-licensing arrangements, forecasts
of future operating results, potential collaborations, and capital
raising activities, timing for bringing any product candidate to
market, involve significant risks and uncertainties and actual
results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are
not limited to, the Company’s dependence on business collaborations
or availability of required financing from capital markets, or
other sources on acceptable terms, if at all, in order to further
develop our products and finance our operations, new product
development (including clinical trials outcome and regulatory
requirements/actions), the risk that we or any of our collaborators
may be unable to secure regulatory approval of and market our drug
candidates, risks associated with the outcome of pending litigation
and competitive risks to marketed products, and the Company’s
ability to repay its outstanding indebtedness, if and when
required, as well as the risks discussed in the Company’s filings
with the Securities and Exchange Commission. The Company is
not under any obligation, and the Company expressly disclaims any
obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor
Contact:Dr. Chau ChengSenior Director, Investor
Relations & Corporate Secretary(973) 605-8200, extension
123ccheng@immunomedics.com
Media Contact:Dan Zacchei /
Josh HochbergSloane & Company212-486-9500
Dzacchei@sloanepr.comJhochberg@sloanepr.com
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024